Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China.
Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.
Ann Rheum Dis. 2020 Jun;79(6):829-836. doi: 10.1136/annrheumdis-2020-217176. Epub 2020 Apr 6.
To evaluate the associations of regular glucosamine use with all-cause and cause-specific mortality in a large prospective cohort.
This population-based prospective cohort study included 495 077 women and men (mean (SD) age, 56.6 (8.1) years) from the UK Biobank study. Participants were recruited from 2006 to 2010 and were followed up through 2018. We evaluated all-cause mortality and mortality due to cardiovascular disease (CVD), cancer, respiratory and digestive disease. HRs and 95% CIs for all-cause and cause-specific mortality were calculated using Cox proportional hazards models with adjustment for potential confounding variables.
At baseline, 19.1% of the participants reported regular use of glucosamine supplements. During a median follow-up of 8.9 years (IQR 8.3-9.7 years), 19 882 all-cause deaths were recorded, including 3802 CVD deaths, 8090 cancer deaths, 3380 respiratory disease deaths and 1061 digestive disease deaths. In multivariable adjusted analyses, the HRs associated with glucosamine use were 0.85 (95% CI 0.82 to 0.89) for all-cause mortality, 0.82 (95% CI 0.74 to 0.90) for CVD mortality, 0.94 (95% CI 0.88 to 0.99) for cancer mortality, 0.73 (95% CI 0.66 to 0.81) for respiratory mortality and 0.74 (95% CI 0.62 to 0.90) for digestive mortality. The inverse associations of glucosamine use with all-cause mortality seemed to be somewhat stronger among current than non-current smokers (p for interaction=0.00080).
Regular glucosamine supplementation was associated with lower mortality due to all causes, cancer, CVD, respiratory and digestive diseases.
在一项大型前瞻性队列研究中，评估常规使用氨基葡萄糖与全因和特定原因死亡率的相关性。
本基于人群的前瞻性队列研究纳入了来自英国生物库研究的 495077 名女性和男性（平均（SD）年龄，56.6（8.1）岁）。参与者于 2006 年至 2010 年招募，并随访至 2018 年。我们评估了全因死亡率和心血管疾病（CVD）、癌症、呼吸和消化疾病导致的死亡率。使用 Cox 比例风险模型计算全因和特定原因死亡率的 HRs 和 95%CI，并对潜在混杂变量进行调整。
在基线时，19.1%的参与者报告常规使用氨基葡萄糖补充剂。在中位随访 8.9 年（IQR 8.3-9.7 年）期间，记录了 19882 例全因死亡，包括 3802 例 CVD 死亡、8090 例癌症死亡、3380 例呼吸疾病死亡和 1061 例消化疾病死亡。在多变量调整分析中，与使用氨基葡萄糖相关的 HRs 分别为全因死亡率 0.85（95%CI 0.82 至 0.89）、CVD 死亡率 0.82（95%CI 0.74 至 0.90）、癌症死亡率 0.94（95%CI 0.88 至 0.99）、呼吸死亡率 0.73（95%CI 0.66 至 0.81）和消化死亡率 0.74（95%CI 0.62 至 0.90）。氨基葡萄糖使用与全因死亡率之间的反比关系在当前吸烟者中似乎比非当前吸烟者略强（交互作用的 p 值=0.00080）。
常规氨基葡萄糖补充与全因、癌症、CVD、呼吸和消化疾病导致的死亡率降低相关。
